Physician profile
Audrey B Gibson
NPI 1053346296
$301,776.01
in general payments reported to CMS, 2019-2025
29 companies · $113K in 2025
The $113K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8,552 · 2022: $40K · 2023: $73K · 2024: $67K · 2025: $113K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $148K · Travel and Lodging: $50K · Consulting Fee: $39K · Food and Beverage: $17K · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $148,040.00 |
| Travel and Lodging | $49,513.91 |
| Consulting Fee | $38,525.00 |
| Food and Beverage | $17,185.28 |
| Education | $136.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $137,092.29 | 2021-2025 | |
| Janssen Biotech, INC. | $75,556.22 | 2021-2025 | Simponi Aria, Tremfya |
| Genzyme Corporation | $22,608.30 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18,382.20 | 2021-2025 | Ofev |
| Novartis Pharmaceuticals Corporation | $18,123.37 | 2021-2025 | Cosentyx |
| Janssen Scientific Affairs, LLC | $12,850.69 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $6,973.98 | 2021-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals Lp | $3,870.50 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $1,682.28 | 2021-2022 | |
| Eli Lilly and Company | $1,600.00 | 2025 | Taltz |
| Amgen INC. | $1,010.62 | 2021-2025 | Enbrel, Otezla, Tavneos |
| E.R. Squibb & Sons, L.L.C. | $561.59 | 2021-2025 | Orencia |
| Pfizer INC. | $479.91 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $243.41 | 2022-2025 | Lupkynis |
| Sobi, INC | $142.69 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $119.86 | 2021-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $87.91 | 2021-2025 | Benlysta |
| Genentech USA, INC. | $79.74 | 2023-2025 | Actemra, Gazyva |
| Organon LLC | $68.80 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $41.50 | 2021-2024 | Opsumit |
| Fresenius Kabi USA, LLC | $34.25 | 2023 | Idacio |
| Ani Pharmaceuticals, INC. | $31.16 | 2025 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $31.14 | 2025 | General - Pain Management |
| Kiniksa Pharmaceuticals, Ltd. | $19.81 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $19.70 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.04 | 2024 | Strensiq |
| Octapharma USA, INC. | $16.41 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.05 | 2024 | Truxima |
| Radius Health, INC. | $14.59 | 2024 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.